Agile Press release: Two new therapies to be tested in ground-breaking COVID-19 clinical trial
The trial will be funded by over £3m of investment from GlaxoSmithKline and Vir Biotechnology
GlaxoSmithKline and Vir Biotechnology have joined forces with researchers from the Universities of Liverpool and Southampton, who are leading an accelerated early phase trials platform to test new treatments for COVID-19. The two monoclonal antibody therapies, VIR-7831 and VIR-7832, will be given to patients who have tested positive for COVID-19 and have mild or moderate symptoms. Pre-clinical studies have already shown that these antibody therapies have promising results in combatting coronavirus infections. The hope is that, by conducting early phase human trials, the researchers will discover whether they could be an effective tool for treating patients with the COVID-19 in the future. Read the complete press release.
Other posts
AGILE trial reports on antiviral activity of molnupiravir in vaccinated and unvaccinated individuals infected with contemporaneous variants of SARS-CoV-2
The antiviral drug molnupiravir received regulatory approval for treating people with mild to moderate COVID-19…
First antiviral pill to treat Covid-19 approved in UK
A “game-changing” antiviral pill that is part of the AGILE Coronavirus Drug Testing Initiative has…
AGILE Covid-19 drug testing platform opens new trial in South Africa
A new international trial to assess whether high doses of the antiparasitic drug nitazoxanide could…
First patient dosed in latest stage of AGILE COVID-19 drug trial
LIVERPOOL, England, 20 April 2021 — The University of Liverpool, Liverpool School of Tropical Medicine,…
People across the south to be part of pioneering research in the fight against COVID-19
People across the south are being asked to play their part in helping vital research…
Government funding boost for COVID-19 drug testing platform
The AGILE drug testing platform has received a multi-million pound award from the UK government’s…